Gladstone Institutes

Human brain vascular multi-omics elucidates disease-risk associations Reid et al. develop MultiVINE-seq to map thousands of non-coding disease variants to genes in human brain vascular cells. Cerebrovascular disease variants compromise vessel integrity, whereas Alzheime...

🚨 NEW PUBLICATION 🚨 "Human brain vascular multi-omics elucidates disease-risk associations"

www.cell.com/neuron/abstr...

@ucsanfrancisco.bsky.social
@madiganreid.bsky.social
@cellpress.bsky.social

Grayson Perry stopped by Gladstone last week to interview investigator Katie Pollard about how her lab uses AI to better understand disease. Pollard will be featured in an upcoming documentary. Keep an eye out! 👀

YouTube video by Gladstone Institutes Why Gladstone Isn’t Like Other Research Institutes | Andrew Garb

Gladstone Trustee Andrew Garb shares why Gladstone’s unique structure as a trust—not a corporation—sets it apart from other research institutes.

Discover how this independence allows Gladstone to move quickly, support bold ideas, and empower scientists to take on high-risk, high-reward projects.

Combination of Two Cancer Drugs May Work Against Alzheimer’s A new study has identified FDA-approved cancer drugs that reverse the gene expression signatures associated with Alzheimer’s.

Read more about this study ⬇️ ⬇️

YouTube video by Gladstone Institutes Discovery Spotlight | Combination of Two Cancer Drugs May Work Against Alzheimer’s

A new study has identified FDA-approved cancer drugs that reverse the gene expression signatures associated with Alzheimer’s.

- YouTube Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

Steve Finkbeiner, director of the Center for Systems and Therapeutics at Gladstone, describes the revolutionary thinking microscope that his team developed to help identify better treatments for diseases like Alzheimer’s, Parkinson’s, and ALS.

YouTube video by Gladstone Institutes Our Research Is Explicitly Focused on Solving Disease | The Gladstone Difference

At Gladstone, we're 100% dedicated to disease-focused research, with more than 600 biologists, chemists, engineers, and data scientists who bring a deeply mechanistic understanding of how the human body works and what goes wrong in disease.

Learn more about the Gladstone Difference.

🚨 NEW PUBLICATION 🚨 "Pregnancy and lactation induce distinct immune responses to #COVID19 booster vaccination and SARS-CoV-2 breakthrough infection" from the Roan Lab in
@jci-insight.bsky.social

YouTube video by Gladstone Institutes Discovery Spotlight | Pregnancy, Lactation Shape Immune Response to COVID-19 Vaccine and Infection

A team of scientists, led by Nadia Roan, found that pregnant and lactating women have strong immune defenses to COVID-19, and identified key benefits that could guide future vaccine design.

Meet Yazmin Martinez Portilla! She's a PUMAS intern working in the lab of Karin Pelka.

For National Intern Day, Martinez Portilla will be taking over Gladstone's Instagram account to show you what it's like to be an intern!

Tune in tomorrow on Instagram: www.instagram.com/gladstoneins...

Meet Diego Ruiz Arvizo! He's a PUMAS intern working in the lab of Alex Marson.

Tomorrow for National Intern Day, Ruiz Arvizo will be taking over our Instagram account to show you what it's like to be an intern.

Be sure to tune in tomorrow, July 31, on Instagram: www.instagram.com/gladstoneins...

Targeting RUNX1 in Macrophages Facilitates Cardiac Recovery Despite major advances in disease treatment, our understanding of how damaged organs recover remains limited. The molecular mechanisms that govern organ plasticity and drive recovery from pathological...

Proud to share new work led by the amazing #junedh_amrute identifying RUNX1 as a key regulator of human cardiac recovery. A druggable macrophage epigenetic program that governs organ recovery. Grateful my lab was part of this effort. #LavineLab @gladstoneinst.bsky.social @amgen.bsky.social

Deepak Srivastava shares how discoveries and scientists from one building in San Francisco are shaping research and innovation worldwide. From groundbreaking science to global leaders in biomedical research, Gladstone’s impact reaches every corner of the world.

#BiomedicalResearch

Blood Vessels and Immune Cells Drive Risk for Alzheimer’s and Stroke Gladstone scientists show that known genetic risk factors for neurological diseases act in the brain’s blood vessels and immune cells, revealing new targets for therapies.

Gladstone scientists show that known genetic risk factors for neurological diseases act in the brain’s blood vessels and immune cells, revealing new targets for therapies.

How Two Existing Cancer Medications May Reverse Alzheimer’s Symptoms Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in the brain during Alzheimer’s, potentially slowing or even…

A new study finds FDA-approved drugs that reverse the gene expression signatures associated with Alzheimer’s.

Scientists Find 2 Existing Drugs Can Reverse Alzheimer's Brain Damage in Mice In efforts to beat Alzheimer's disease, researchers are looking at existing drugs that could tackle the condition, and a new study identifies two promising candidates that are currently used to treat…

In efforts to beat Alzheimer's disease, researchers are looking at existing drugs that could tackle the condition. A new study from Gladstone and UCSF identifies two promising candidates that are currently used to treat cancer.

@ucsanfrancisco.bsky.social
@ucsf-bchsi.bsky.social

A team of Gladstonians participated in the San Francisco AIDS walk earlier this week! Shoutout to everyone who participated and helped raise money for the cause!

Could cancer drugs be the future of Alzheimer's treatment? In a new study, two cancer drugs showed signs of slowing or reversing symptoms of Alzheimer’s disease.

Gladstone Investigator Yadong Huang comments on a new study he helped lead, in which two cancer drugs showed signs of slowing or reversing symptoms of Alzheimer’s disease.

History For more than 40 years, Gladstone Institutes has been driving transformative biomedical discovery across high-need disease areas. An independent, nonprofit research organization based in San Francisco...

Read more about Gladstone's history: gladstone.org/about/history

J. David Gladstone’s gift of $8 million to fund student scholarships has turned into a thriving and highly respected biomedical research organization that brings together the best minds to focus on one goal—using science to overcome disease.

Gladstone launched a campaign to expand Gladstone’s footprint, hire hundreds of additional scientists, and seize emerging opportunities for high-impact biomedical research that can overcome disease.

The joint Gladstone-UCSF Institute of Genomic Immunology was launched under the direction of Alex Marson, bringing together experts in various fields to develop the next generation of immunotherapies to fight cancer and autoimmune disorders.

Under the leadership of Melanie Ott, the renamed Gladstone Institute of Virology quickly pivoted their work to study SARS-COV-2, the virus that causes COVID-19.

After an extensive search, Benoit Bruneau was selected as the new director of the Gladstone Institute for Cardiovascular Disease, where researchers are working to tackle one of the world’s leading causes of death.

Gladstone launched the Gladstone Institute of Data Science and Biotechnology, under the direction of Katie Pollard, with the goal of creating a central hub where mathematicians, engineers, and biologists can work closely together.

Deepak Srivastava became president of Gladstone. His presidency has been characterized by focusing on emerging technologies such as AI, gene-editing, and stem cell research to advance science and bring cures closer to patients.

Sandy Williams became the second president of Gladstone. He led the effort to increase philanthropic gifts and focused on bringing the science closer to patients by increasing revenues from IP and through sponsored research agreements with the commercial sector.

Gladstone had outgrown its old space at San Francisco General Hospital, and in 2004, scientists moved their labs under one roof into a new facility in Mission Bay, a neighborhood that would become the heart of the biotech industry in the city.

Since 1998, scientists in the Gladstone Institute of Neurological Disease, led by Lennart Mucke, have used multipronged approaches and outside-the-box thinking to study neurodegenerative disorders.

The Gladstone Institute of Virology and Immunology was launched under Warner Greene. Their work led to foundational discoveries about HIV and paved the way for PrEP therapies that reduce the risk of HIV infection.